The analysis presented on the website is based on the data from newest edition (2025).

You can also preview the analysis from previous editions (for 2022-20223 editions also in SK, HU and CS).

Disease landscape

Multiple Sclerosis

Sigificant restrictions in access to multiple sclerosis treatment and diagnosis have been identified in the Visegrád Group (V4) countries as measured in the GAP score. Results vary moderately from country to country and the difference between the highest and the lowest scoring country is 12 points. The main reason for the relatively unfavourable assessment is very low percentage of patients treated with sphingosine 1-phosphate receptor modulators in all the V4 countries.

Cross-Country

General GAP for Multiple Sclerosis

Poland

52.9

Hungary

55

Czechia

67.2

Slovakia

65.6

Compliance with guidelines

Positive recommendations for 12 multiple sclerosis drugs were found in clinical practice guidelines and almost all of them (9-11 drugs) are available to multiple sclerosis patients in every V4 country.

From registration to reimbursement

Population burden

DALY* - Rate per 100k

*disability adjusted life-years

Target population

Sphingosine 1-phosphate receptor modulators 2ND generation

Drug access

Number of patients treated (2023)

Drug access

Population treated (%)*
Sphingosine 1-phosphate receptor modulators (2g)

*percentage of the population potentially eligible for treatment with S1P 2G

Main issues

  • The average time to reimbursement for multiple sclerosis drugs in the V4 countries is more than 2.2 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 1.8 year.
  • Sphingosine 1-phosphate receptor modulators’ reimbursement was implemented in 2021-2022 in V4 states an and in 2023 the share of the target population treated with these preparations remained very low (3-11% of potential patients) across the region.
  • Population burden in V4 states is much lower than the European Union average. A decreasing trend or stabilization of DALY values was observed in V4 states in past years.

Project

We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).